Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Consensus

Buy

Average target

$127.00

Implied upside

—

Analysts

24

Why Is BSX Down Today?

Boston Scientific shares declined 0.48% today amid a confluence of negative catalysts, including a significant Citigroup downgrade and an FDA recall of its LUX Dx cardiac monitor. The stock is trading at a substantial discount following a 55% slump, reflecting investor concerns about the company's recovery trajectory and near-term headwinds.

Bottom line: Boston Scientific faces near-term headwinds from analyst downgrades and a product recall that have contributed to today's decline and the broader 55% stock slump. While the depressed valuation may appeal to value investors, the uncertain recovery path and competitive pressures warrant caution until management demonstrates concrete evidence of operational improvement and risk remediation.